Integrated analysis of systemic inflammation and tumor immune features identifies biologically distinct patient subgroups with differential survival outcomes, outperforming conventional biomarkers The ...
Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...
Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...
Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the pivotal CheckMate 816 trial, which established neoadjuvant nivolumab plus ...
This retrospective observational study reviewed electronic medical records for all patients with lung cancer diagnosed at King Hussein Cancer Center from January 1, 2017, to April 1, 2024. Included ...
Soluble immune checkpoint biomarkers comprise circulating forms of inhibitory molecules that ordinarily regulate T-cell activation via receptor–ligand interactions at the cell surface. Generated by ...
Tarlatamab combined with PD-L1 inhibitors shows potential in improving survival for ES-SCLC, with a median OS of 25.3 months. The combination may bypass tumor immune evasion by redirecting T-cells to ...
AI-based image analysis models can predict cancer biomarkers and patient survival more accurately than conventional methods, enhancing treatment outcomes. Caris Life Sciences' AI model analyzed over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results